This proposal is based on the novel finding that in addition to activating downstream components of the DNA damage response (DDR), the Mre11 complex-ATM arm of the DDR is required to activate a p53-dependent epigenetic program in response to oncogene activation. This pathway appears to parallel that governed by Ink4a-p19Arf. We will carry out quantitative analysis of the abundance and location of chromatin marks arising in response to the activation of neuT and c-myc, and assess changes in the expression of chromatin modifying enzymes in epithelial cells. To determine whether these responses are shared by hematopoietic cells, we will examine the same endpoints as well as the onset and progression of malignancy in p53-/- and Mre11ATLD1/ATLD1 bone marrow following introduction of c-myc or the Nup98-Hox9a cDNA. Finally, having defined these features of the p53-dependent epigenetic response to oncogene, we will identify enzymes that mediate this response and test the hypothesis that this p53-dependent function which requires DDR signaling is tumor suppressive. Collectively, the experiments proposed will illuminate a previously undescribed connection between p53 and the upstream components of the DDR that effects a barrier to oncogene-driven carcinogenesis. Therefore, this proposal is highly significant with the potential to provide novel mechanistic insight regarding tumor suppression by p53.
Genome instability is a hallmark of cancer, and defects in the DNA damage response, which is required for the maintenance of genome stability are associated with cancer as well as human syndromes associated with reproductive, developmental and neurological defects. This proposal addresses a non-canonical function of the DNA damage response that is mediated by the Mre11 complex and p53 in response to oncogene activation. This novel pathway culminates in the elaboration of heterochromatin changes that suppress oncogene driven carcinogenesis. The experiments described in this application have the potential to provide insights regarding novel mechanisms underlying tumor suppression effected by the DNA damage response and p53, as well as those that may present suitable targets for interdiction in therapeutic settings.
| Rastogi, Chaitanya; Rube, H Tomas; Kribelbauer, Judith F et al. (2018) Accurate and sensitive quantification of protein-DNA binding affinity. Proc Natl Acad Sci U S A 115:E3692-E3701 |
| Baugh, Evan H; Ke, Hua; Levine, Arnold J et al. (2018) Why are there hotspot mutations in the TP53 gene in human cancers? Cell Death Differ 25:154-160 |
| Agmon, Eran; Solon, Jérôme; Bassereau, Patricia et al. (2018) Modeling the effects of lipid peroxidation during ferroptosis on membrane properties. Sci Rep 8:5155 |
| Yozwiak, Carrie E; Hirschhorn, Tal; Stockwell, Brent R (2018) Toward a Microparticle-Based System for Pooled Assays of Small Molecules in Cellular Contexts. ACS Chem Biol 13:761-771 |
| Hirschhorn, Tal; Stockwell, Brent R (2018) The development of the concept of ferroptosis. Free Radic Biol Med : |
| Liu, Hengrui; Schreiber, Stuart L; Stockwell, Brent R (2018) Targeting Dependency on the GPX4 Lipid Peroxide Repair Pathway for Cancer Therapy. Biochemistry 57:2059-2060 |
| Conrad, Marcus; Kagan, Valerian E; Bayir, Hülya et al. (2018) Regulation of lipid peroxidation and ferroptosis in diverse species. Genes Dev 32:602-619 |
| Zhang, Yan; Larraufie, Marie-Hélène; Musavi, Leila et al. (2018) Design of Small Molecules That Compete with Nucleotide Binding to an Engineered Oncogenic KRAS Allele. Biochemistry 57:1380-1389 |
| Shimada, Kenichi; Reznik, Eduard; Stokes, Michael E et al. (2018) Copper-Binding Small Molecule Induces Oxidative Stress and Cell-Cycle Arrest in Glioblastoma-Patient-Derived Cells. Cell Chem Biol 25:585-594.e7 |
| Gaschler, Michael M; Andia, Alexander A; Liu, Hengrui et al. (2018) FINO2 initiates ferroptosis through GPX4 inactivation and iron oxidation. Nat Chem Biol 14:507-515 |
Showing the most recent 10 out of 159 publications
